439 results on '"Lee, Eudocia Q"'
Search Results
2. National Cancer Institute Collaborative Workshop on Shaping the Landscape of Brain Metastases Research: challenges and recommended priorities
3. Neurotoxicity of Cancer Immunotherapies Including CAR T Cell Therapy
4. Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results
5. Glioblastoma Clinical Trials: Current Landscape and Opportunities for ImprovementCurrent Glioblastoma Clinical Trial Landscape
6. Re-irradiation of recurrent IDH-wildtype glioblastoma in the bevacizumab and immunotherapy era: Target delineation, outcomes and patterns of recurrence
7. Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients.
8. First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma
9. Supplementary Table S3 from Clinical and Genomic Predictors of Adverse Events in Newly Diagnosed Glioblastoma
10. Supplementary Figure S1 from Clinical and Genomic Predictors of Adverse Events in Newly Diagnosed Glioblastoma
11. Barriers to accrual and enrollment in brain tumor trials
12. Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial
13. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
14. A practical guide to neuro-oncology fellowship
15. Burnout and career satisfaction in young neuro-oncology investigators: Results of the Society for Neuro-Oncology Young Investigator Survey.
16. Immune checkpoint inhibitors in GBM
17. Neurological complications of systemic cancer and antineoplastic therapy
18. Neurological complications of hematopoietic stem cell transplantation
19. Contributors
20. Progestin-associated meningiomatosis with unusual schwannoma-like morphology
21. Clinical and Genomic Predictors of Adverse Events in Newly Diagnosed Glioblastoma
22. Neurological Complications of Immune-Based Therapies
23. Neurological Complications of Targeted Therapies
24. Therapeutic Advances in Neuro-Oncology
25. Response Assessment in Neuro-Oncology Clinical Trials
26. Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations
27. Abnormal vascular structure and function within brain metastases is linked to pembrolizumab resistance.
28. Defining interventions and metrics to improve diversity in CNS clinical trial participation: A SNO and RANO effort.
29. Integration of rare cell capture technology into cytologic evaluation of cerebrospinal fluid specimens from patients with solid tumors and suspected leptomeningeal metastasis
30. The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab
31. Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization
32. Defining interventions and metrics to improve diversity in CNS clinical trial participation: a SNO and RANO effort
33. Abnormal vascular structure and function within brain metastases is linked to pembrolizumab resistance
34. Neurologic Complications of Cancer Therapies
35. Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases
36. Author Correction: Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases
37. Mechanisms and therapeutic implications of hypermutation in gliomas
38. Neurologic Complications of Hematopoietic Stem Cell Transplantation
39. Clinical Trial Considerations in Neuro-oncology
40. Structural and functional vascular dysfunction within brain metastases is linked to pembrolizumab inefficacy
41. Data from Bavituximab Decreases Immunosuppressive Myeloid-Derived Suppressor Cells in Newly Diagnosed Glioblastoma Patients
42. Supplementary Data 1 from Bavituximab Decreases Immunosuppressive Myeloid-Derived Suppressor Cells in Newly Diagnosed Glioblastoma Patients
43. Neurological Complications of Targeted Therapies
44. Neurological Complications of Immune-Based Therapies
45. Brain Tumors
46. Neurological Complications of Targeted Therapies and Immunotherapies for Cancer
47. The Evolving Landscape of Brain Metastasis
48. Impact of pemetrexed on intracranial disease control and radiation necrosis in patients with brain metastases from non-small cell lung cancer receiving stereotactic radiation
49. Local control after brain-directed radiation in patients with cystic versus solid brain metastases
50. Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.